Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2020-12-02 Capital/Financing Update
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
FULL EXERCISE OF THE OVER-ALLOTMENT OPTION STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the full exercise of the over-allotment option, stabilizing actions, and the end of the stabilization period related to a global offering of shares by RemeGen Co., Ltd. It includes details about share allotment, shareholding structure changes, use of proceeds, and regulatory compliance with the Stock Exchange listing rules. The content focuses on capital raising activities and share issuance rather than financial results, management changes, or legal matters. The document is not a full financial report but an update on financing and capital structure changes following a public offering. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9487 characters) and detailed content support this classification with high confidence.
2020-12-02 English
DISCLOSEABLE TRANSACTION FURTHER DISPOSAL OF LISTED SECURITIES IN TONGCHENG-ELONG
Capital/Financing Update Classification · 95% confidence The document is an announcement by Overseas Chinese Town (Asia) Holdings Limited regarding the disposal of listed securities in Tongcheng-Elong. It details the transaction specifics, including the number of shares sold, sale price, proceeds, and the implications under the Listing Rules. The document is structured as a formal announcement of a transaction rather than a financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the capital transaction and compliance with listing rules. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length and content confirm it is not a brief notice or a report publication announcement but a substantive announcement of a capital transaction.
2020-12-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/11/2020 and submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related activities. The content focuses on share capital changes and movements rather than financial performance, earnings, or management commentary. It is a regulatory disclosure about share capital movements rather than a financial report or earnings release. This type of document fits best under 'Capital/Financing Update' (CAP) as it provides updates on the company's capital structure and share capital changes.
2020-12-01 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 30 November 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/11/2020 and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. It includes confirmations by the company secretary regarding compliance with listing rules and legal requirements. The content focuses on share capital changes and securities issuance details for a specific month, without financial statements or earnings data. This type of document is a regulatory filing reporting share capital movements and confirmations to the stock exchange, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive data. Therefore, the best classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-11-30 English
MAJOR TRANSACTION FURTHER DISPOSAL OF LISTED SECURITIES IN TONGCHENG-ELONG
Capital/Financing Update Classification · 95% confidence The document is an announcement by Overseas Chinese Town (Asia) Holdings Limited regarding a major transaction involving the further disposal of listed securities in Tongcheng-Elong. It details the fourth disposal of shares, references previous disposals, and discusses the implications under the Listing Rules, including shareholder approvals and percentage ratios. The document includes transaction details, consideration, and reasons for the disposal. It is a regulatory announcement about a significant capital transaction (disposal of shares) and does not contain financial statements or detailed financial reports. It is not a full financial report, earnings release, or management discussion, but rather an update on a capital transaction subject to regulatory disclosure requirements. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (over 14,000 characters) and detailed transaction information support this classification with high confidence.
2020-11-20 English
VOLUNTARY ANNOUNCEMENT - c-MetADC (RC108) OBTAINED INVESTIGATIONAL NEW DRUG (IND) APPROVAL FROM NMPA FOR c-Met POSITIVE ADVANCED SOLID TUMOR IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by RemeGen Co., Ltd. regarding the approval of their drug candidate RC108 for clinical trials by the China National Medical Products Administration (NMPA). It is an update on a business development related to drug approval and clinical trial progress. The document is relatively short (3421 characters) and does not contain financial statements, detailed financial data, or regulatory certifications. It is not an annual or interim report, earnings release, or any form of financial filing. It is also not a regulatory filing or certification. The content is a business progress announcement related to product development and regulatory approval, which fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-11-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.